Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
Rezpeg demonstrated modest efficacy and good safety in AtD Phase 2b but faces stiff competition from established biologics like Dupixent. Phase 2b AA results for the company were mixed, with efficacy falling short of JAK inhibitor benchmarks on SALT20 and high attrition complicating interpretation. With a ~$900M market cap and cash runway into Q2 2027, I maintain a cautious Hold on NKTR stock pending clearer data on Rezpeg's commercial potential. Klaus Vedfelt/DigitalVision via Getty Images Nektar Overview Nektar Therapeutics' ( NKTR ) lead clinical-stage asset, "Rezpeg," effectively and selectively expands Tregs in the blood in an attempt to modulate the immune system response to autoimmune and skin conditions. Formerly known as LY3471851, Rezpeg This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote thi
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by analysts at BTIG Research from $100.00 to $118.00. They now have a "buy" rating on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- iShares MSCI EAFE Growth ETF declares semi-annual distribution of $1.8057 [Seeking Alpha]Seeking Alpha
- iShares MSCI Indonesia ETF declares semi-annual distribution of $0.1615 [Seeking Alpha]Seeking Alpha
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 12/16/25 - Form 8-K
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- NKTR's page on the SEC website